RNAseq of primary and recurrent ovarian cancer tumors with and without BRCA1/2 mutations

RNAseq was generated for a cohort of ovarian cancer patients to identify gene expression changes between primary and recurrent ovarian cancer tumors from patients with and without BRCA1/2 mutations Overall design: We performed RNAseq in 62 primary and recurrent tumors from 28 patients with stage III/IV high grade serous ovarian cancer (HGSOC), of which 11 patients carried germline, pathogenic BRCA1 and/or BRCA2 mutations. [Update] 05-20-2024: The Sample titles were updated. The original titles are in the Sample description field.